This Month in JNM

Folic acid radioconjugates: Müller and Schibli describe current folate receptor–targeting strategies and summarize the promise of several folic acid radioconjugates for SPECT and PET oncologic applications. Page 1

PET probe for melanoma: Minn and Vihinen offer commentary on current practices in PET staging of melanoma, focusing on a novel tracer described in this issue of JNM with potential for detection of regional lymph node metastases.Page 5

Cortical networks and PET: Kumar and Chugani review the use of ¹⁸F-FDG PET in elucidating cortical networks underlying a range of neurocognitive dysfunction and preview an article in this issue of JNM on its utility in postencephalitic epilepsy.Page 8

Vascular inflammation and PET: Yoo and colleagues use ¹⁸F-FDG PET to examine the severity of vascular inflammation in healthy individuals without hyperlipidemia but with elevated high-sensitivity C-reactive protein.Page 10

Time corrections of tumor SUVs: Stahl and colleagues present a simple, algebraically deduced method using a single reference point to make straightforward time corrections of tumor SUVs in ¹⁸F-FDG PET of breast cancer.Page 18

¹¹C-PBR28 PET and translocator protein binding: Owen and colleagues explore whether mixed-affinity binding characteristics in multiple sclerosis can be detected in brain tissue and blood from individuals with no history of neurologic disease.Page 24

¹¹C-PK11195 in vasculitides: Lamare and colleagues investigate whether PET/CT angiography using a selective ligand for the translocator protein 18 kDa, expressed in activated macrophages, can allow imaging and quantification of arterial wall inflammation in patients with large-vessel vasculitis.Page 33

PET in FIRES: Mazzuca and colleagues describe the utility of ¹⁸F-FDG PET in identifying the location of neocortical dysfunction in pediatric febrile infection–related epilepsy syndrome, a recently described entity of unknown etiology.Page 40

Monitoring antiangiogenic therapy response: de Langen and colleagues assess the predictive value of combined PET, CT, and MR data during antiangiogenic treatment in patients with advanced non–small cell lung cancer.Page 48

Follow-up scintigraphy in DTC: de Meer and colleagues question the value added by follow-up diagnostic radioiodine whole-body scintigraphy to recombinant human thyroid-stimulating hormone–stimulated thyroglobulin measurement in high-risk patients with differentiated thyroid cancer.Page 56

Myocardial OEF and dynamic ¹⁵O₂ PET: Lubberink and colleagues determine the accuracy of oxygen extraction fraction measurements using a dynamic PET protocol after bolus inhalation of ¹⁵O₂.Page 60

PET/CT after CRT: Uebleis and colleagues use electrocardiogram-gated ¹⁸F-FDG PET/CT to identify differences in responders and nonresponders to cardiac resynchronization therapy, with results that could inform alternative and individualized therapies for nonresponders.Page 67

Localization with ⁹⁰Y PET/CT: Gates and colleagues evaluate the results of PET/CT imaging to determine ⁹⁰Y glass microsphere distribution in patients after implantation for transarterial radiation treatment of liver tumors.Page 72

PET prediction in RA treatment: Elzinga and colleagues assess correlations between changes in ¹⁸F-FDG joint uptake on PET after only 2 wk of infliximab treatment and later clinical outcomes in patients with rheumatoid arthritis.Page 77

PET in prostate cancer: Jadvar provides an educational overview of the role of imaging in prostate cancer and the relative and respective capabilities of ¹⁸F-FDG, ¹⁸F- or ¹¹C-acetate, and ¹⁸F- or ¹¹C-choline in PET imaging in the disease.Page 81

PET, ICH, and stem cells: Feng and colleagues use serial ¹⁸F-FDG PET imaging to assess the efficacy of human mesenchymal stem cells in the treatment of intracerebral hematoma in a primate model.Page 90

Choline metabolism in HCC: Kuang and colleagues examine the relationship between choline metabolism and tracer uptake in ¹¹C-choline PET imaging in an animal model of hepatocellular cancer.Page 98

Imaging TSPO expression in glioma: Buck and colleagues describe preclinical PET studies characterizing a high-affinity aryloxyanilide-based translator protein imaging ligand, a candidate probe for quantitative assessment of translator protein expression in glioma.Page 107

Melanoma lymphoscintigraphy with ¹⁸F-MEL050: Denoyer and colleagues detail the efficacy of differing routes of administration of a new benzamide-based PET radiotracer for imaging regional lymph node metastasis in melanoma.Page 115

⁶⁸Ga-DOTATOC reporter gene imaging: Zhang and colleagues report on a series of validation studies of the human somatostatin receptor subtype 2–⁶⁸Ga-DOTATOC reporter system and potential beneficial aspects in translation to clinical studies.Page 123

Comparing dopamine transporter tracers: Varrone and colleagues examine the kinetics and relative merits of ¹⁸F-FE-PE2I, a novel radioligand for dopamine transporter PET, and ¹¹C-PE2I in nonhuman primates.Page 132

PET and Abraxane treatment: Sun and colleagues investigate whether ¹⁸F-FPPRGD2, an integrin-specific PET tracer, has utility in monitoring early response of breast tumors to Abraxane therapy in preclinical studies.Page 140

¹⁸F-PFH PET for renal imaging: Awasthi and colleagues explore the potential of p-¹⁸F-fluorohippurate for PET imaging to measure effective renal plasma flow and function.Page 147

MRI-assisted PET motion correction: Catana and colleagues apply a novel algorithm for data processing and rigid-body motion correction for an MRI-compatible PET brain scanner prototype and describe the results of phantom and human validation studies.Page 154

ON THE COVER

Head motion is difficult to avoid in long PET studies, degrading image quality and offsetting the benefit of using a high-resolution scanner. As a potential solution, simultaneously acquired MRI data can be used for motion tracking. The prototype dedicated brain scanner shown here, which can be operated inside the bore of an MRI scanner, has the potential to improve PET image quality and to benefit many neurologic applications.

See page 155.

• © 2011 by Society of Nuclear Medicine